Drugs / Secretin
Secretin
also known as
Synthetic Human Secretin · RG1068 · ChiRhoClin · ChiRhoStim · Human Secretin · secretin hydrochloride
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CHIRHOSTIM | — | 2004-04-09 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01371240 | Jun → Dec 2011 | malignant pancreatic neoplasm | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01452217 | Sep 2010 → Sep 2011 | chronic pancreatitis | University of Nottingham | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07651748 | Apr 2025 → Jun 2026 overdue | — | Erasmus Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT03617861 | Nov 2018 → Jul 2019 | dyspepsia | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01265875 | Dec 2010 → Dec 2011 | chronic pancreatitis | ChiRhoClin, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00587132 | Nov 2006 → Feb 2012 | pancreatic adenocarcinoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00235274 | Nov 2005 → Aug 2006 | schizophrenia | Indiana University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03290846 | Aug 2016 → Oct 2019 | obesity disorder | Turku University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00065962 | Jun 1999 → May 2000 | autism | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07285863 | Mar 2026 → Mar 2027 expected | chronic pancreatitis, exocrine pancreatic insufficiency | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT05659147 | Jan 2023 → Dec 2026 expected | diabetes mellitus, pancreatitis | Children's Hospital Medical Center, Cincinnati | Enrolling by invitation | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01094626 | Apr 2010 → Mar 2013 | pancreatic intraductal papillary-mucinous neoplasm | Elizabeth Hecht | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02458118 Background | Jun 2012 → Apr 2016 | chronic pancreatitis | University of Nottingham | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03686618 Comparator | Oct 2018 → Oct 2019 | acute pancreatitis | ChiRhoClin, Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02160808 Comparator | May 2014 → Sep 2019 | pancreas disorder | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05914077 Background | Sep 2023 → Jan 2025 | pancreatic intraductal papillary-mucinous neoplasm | Fundacion Clinic per a la Recerca Biomédica | Unknown | No outcome recorded |
| Phase 3 | NCT04231279 Background | Jan 2022 → Jun 2023 | irritable bowel syndrome | Orlando Health, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02000089 Comparator | Jan 2014 → Dec 2028 expected | Lynch syndrome, Peutz-Jeghers syndrome, malignant pancreatic neoplasm | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT01087801 Comparator | Oct 2007 → Nov 2009 | pancreas disorder | ChiRhoClin, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01134848 Comparator | Jan 2009 → Feb 2010 | biliary dyskinesia | University of Nottingham | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04613700 Comparator | Mar → Sep 2020 | diabetes mellitus, obesity disorder | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT02869893 Background | Aug 2016 → Apr 2017 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| — | NCT01094600 Background | Jun 2012 | malignant pancreatic neoplasm | Columbia University | Withdrawn | No outcome recorded |
| — | NCT01094535 Background | Sep 2007 → Sep 2012 | malignant pancreatic neoplasm | Columbia University | Withdrawn | No outcome recorded |
| — | NCT01094561 Background | Jul 2006 → Feb 2015 | malignant pancreatic neoplasm | Elizabeth Hecht | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secretin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01371240 ↗ |
| Known as | ChiRhoClin | “Secretin (human synthetic) - ChiRhoClin” NCT07285863 ↗ |
| Known as | ChiRhoStim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01087801 ↗ |
| Known as | Human Secretin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265875 ↗ |
| Known as | RG1068 | “A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation)” NCT01371240 ↗1“Secretin's (RG1068) psychophysiological effects” NCT00235274 ↗ |
| Known as | secretin hydrochloride | “participants are single-blinded and randomised to receive placebo (saline) or secretin (secretin hydrochloride) infusions.” NCT03290846 ↗ |
| Known as | Synthetic Human Secretin | “Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion” NCT01087801 ↗ |
| Action | Activate | “secretin receptor activation may provide a novel therapeutic mechanism for patients with FD and rapid gastric emptying.” PMID 32036693 ↗ Feb 2020 |
| Modality | Other / unclassified | “Secretin is a gut hormone with binding sites in the brain.” NCT00065962 ↗ |
| Route | Intravenous | “following the administration of intravenous secretin given as part of endoscopy” NCT00065962 ↗ |